Hyperoxia Therapy of Pre-Proliferative Ischemic Retinopathy in a Mouse Model

Wenbo Zhang, Harumasa Yokota, Zbimin Xu, Subhadra P. Narayanan, Lauren Yancey, Akitoshi Yoshida, Dennis M. Marcus, Robert W. Caldwell, Ruth B. Caldwell, and Steven E. Brooks

**PURPOSE.** To investigate the therapeutic use and mechanisms of action of normobaric hyperoxia to promote revascularization and to prevent neovascularization in a mouse model of oxygen-induced ischemic retinopathy.

**METHODS.** Hyperoxia treatment (HT, 40%-75% oxygen) was initiated on postnatal day (P) 14 during the pre-proliferative stage of ischemic retinopathy. Immunohistochemistry, ELISA, and quantitative PCR were used to assess effects on retinal vascular repair and pathologic angiogenesis in relation to glial cell injury, VEGF protein, and mRNA levels of key mediators of pathologic angiogenesis. Effects of intravitreal injections of VEGF and the VEGF inhibitor VEGFR1/Fc fusion protein were also studied.

**RESULTS.** Administration of HT during the ischemic pre-proliferative phase of retinopathy effectively accelerated the process of revascularization while preventing the development of vitreous neovascularization. HT enhanced the formation of specialized endothelial tip cells at the edges of the repairing capillary networks and blocked the overexpression of several molecular mediators of angiogenesis, inflammation, and extracellular proteolysis. HT markedly reduced the reactive expression of GFAP in Müller cells and improved the morphology of astrocytes in the avascular region of the retina. Exogenous VEGF administered into the vitreous on P14 was not sufficient to cause vitreous neovascularization in the HT mice. Injection of the VEGF antagonist VEGFR1/Fc blocked both pathologic and physiological angiogenesis and did not rescue astrocytes.

**CONCLUSIONS.** HT may be clinically useful to facilitate vascular repair while blocking neovascularization in the pre-proliferative stage of ischemic retinopathy by correcting a broad range of biochemical and cellular abnormalities. (Invest Ophthalmol Vis Sci. 2011;52:6384–6395) DOI:10.1167/iovs.11-7666

Ischemic retinopathy is the leading cause of blindness in persons younger than 60 in the United States. It is a complication of diabetes, retinal vein occlusion, and retinopathy of prematurity, with loss of vision occurring as a result of retinal hypoxia, increased vascular permeability, and pathologic neovascularization (NV). Considerable scientific and clinical investigation have focused on identifying the molecular mediators involved in initiating pathologic angiogenesis in the retina and developing effective inhibitors. Anti-VEGF agents are now in widespread use in the treatment of patients with subretinal neovascularization associated with age-related macular degeneration and are being investigated in clinical trials in diabetic retinopathy. Several antiangiogenic agents are in clinical use to manage a wide variety of conditions involving pathologic angiogenesis and vascular permeability in the eye. Several issues, however, detract from the potential clinical value of these agents.

Whereas antiangiogenic inhibitors are effective in reversing vascular permeability and eliminating NV, this therapy does not address the issue of retinal ischemia or promote the normal vascular repair that is essential to ending tissue hypoxia and maintaining normal function. In fact, an inhibitor’s lack of antiangiogenic selectivity might adversely impact the process of physiological vascular repair. Similarly, suppression of VEGF-mediated cell survival pathways in hypoxic neurons might inhibit neuronal survival and function. In addition, antiangiogenic therapy is not indicated at the pre-proliferative stage of ischemic retinopathy, a time when metabolic support of the retina and repair of the damaged capillary beds are most critical. Delivery of antiangiogenic agents by intravitreal injection also carries a risk for vision-threatening endophthalmitis and uveitis.

The therapeutic use of oxygen has been extensively studied in wound healing, especially in clinical situations in which tissue perfusion is compromised by arterial insufficiency, diabetes, or previous radiation treatment for neoplasia. Numerous studies support the use of hyperbaric oxygen as adjunctive treatment for nonhealing lower extremity wounds in patients with diabetes, compromised tissue flaps and grafts, and radiation-induced ischemic osteonecrosis. Experiments in various animal models of ischemia have suggested that supplemental oxygen can improve the rate of wound healing and reduce apoptosis in the affected tissue. In addition to supporting oxidative phosphorylation, oxygen plays a critical role in redox signaling for cytokines, including VEGF and PDGF, and in cell motility, integrin function, and leukocyte recruitment.
The therapeutic effects of oxygen supplementation in ischemic retinopathy have not been well characterized. However, it has been shown that hyperbaric oxygen treatment reduces breakdown of the blood-retinal barrier in streptozotocin-induced diabetic rats. In humans, small case series have suggested that normobaric supplemental oxygen can reduce vascular permeability and retinal thickness in diabetic macular edema and central retinal vein occlusion. Oxygen supplementation immediately after vaso-obliteration but before the onset of retinal hypoxia was also shown to reduce the severity of vitreous NV and to attenuate the degeneration of astrocytes in oxygen-induced retinopathy (OIR) models. These clinical and scientific studies support the potential value of oxygen therapy as a primary or adjunctive treatment for vision-threatening ischemic retinopathies.

In the present study, we investigated the therapeutic benefit of oxygen supplement during the ischemic pre-proliferative phase of ischemic retinopathy in an OIR mouse model. Unlike other studies that start treatment of ischemic retinopathy before the onset of hypoxia, we initiated hyperoxia treatment after a period of retinal ischemia, when the multiple signs of ischemic retinopathy—such as no perfusion in the central retina, tortuous and dilated vessels, and upregulation of many angiogenic and inflammatory genes in the retina—are evident. This delay was chosen to determine the potential clinical use of HT in the pre-proliferative stage of ischemic retinopathy because most patients with ischemic retinopathy seek evaluation before NV has developed. We show that normobaric HT after a period of retinal ischemia selectively blocks the development of pathologic NV while it simultaneously accelerates the process of physiologic revascularization. Mechanistically, we further demonstrate the beneficial effect of HT may be attributed to its pleiotropic effect by correcting a broad range of biochemical and cellular abnormalities. Our data strongly support the potential of hyperoxia as an effective primary or adjunctive therapy for pre-proliferative ischemic retinopathy.

**METHODS**

**Treatment of Animals**

All procedures with animals were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the institutional animal care and use committee. Mice were anesthetized by intraperitoneal injection of anesthetic (trihalomethanol; Avertin; 625 mg/kg). Intravitreal injections were performed by delivering 1 μL PBS containing 2 μg VEGF/Fc fusion protein or mouse VEGF (R&D Systems, Minneapolis, MN) or vehicle only with a 36-gauge needle mounted to a 10-μL Hamilton syringe. The tip of the needle was inserted under the guidance of a dissecting microscope (Wild M650; Leica, Bannockburn, IL) through the dorsal limbus of the eye. Injections were performed slowly throughout a period of 2 minutes.

**Intravitreal Injection**

Mice were anesthetized by intraperitoneal injection of anesthetic (trihalomethanol; Avertin; 625 mg/kg). Intravitreal injections were performed by delivering 1 μL PBS containing 2 μg VEGF/Fc fusion protein or mouse VEGF (R&D Systems, Minneapolis, MN) or vehicle only with a 36-gauge needle mounted to a 10-μL Hamilton syringe. The tip of the needle was inserted under the guidance of a dissecting microscope (Wild M650; Leica, Bannockburn, IL) through the dorsal limbus of the eye. Injections were performed slowly throughout a period of 2 minutes.

**Immunostaining on Wholemount Retinas**

Retinas were carefully dissected, blocked, and permeabilized in PBS containing 10% goat serum and 1% Triton-X-100 for 30 minutes. Then retinas were incubated with Alex 488–conjugated goat anti-rabbit antibody at 1:400 (Invitrogen) for 4 hours at 4°C. Retinas were washed with PBS, mounted on microscope slides in mounting medium (Vectashield; Vector Laboratories, Burlingame, CA), and examined by fluorescence microscopy (Axioptot; Carl Zeiss, Thornwood, NY) and by confocal microscopy (Zeiss 510; Carl Zeiss). Areas of vaso-obliteration and vitreoretinal neovascular tufts were quantified by using ImageJ software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html) as reported.

**Immunostaining on Retinal Sections**

After eyes were fixed in 4% paraformaldehyde, retinas were carefully dissected, equilibrated in 30% sucrose, embedded in optimal cutting compound high in liquid nitrogen, and cut into 10-μm sections. Retinal sections were permeabilized in PBS containing 1% Triton-X-100 for 30 minutes at room temperature and blocked with 3% normal goat serum for 30 minutes. Sections were incubated overnight at 4°C with rabbit polyclonal anti-GFAP antibody. After washing in PBS, sections were incubated with Alexa 488–conjugated goat anti-rabbit antibody at 1:500 (Invitrogen) for 4 hours at 4°C. Retinas were washed with PBS, mounted on microscope slides in mounting medium (Vectashield; Vector Laboratories, Burlingame, CA), and examined by fluorescence microscopy (Axioptot; Carl Zeiss, Thornwood, NY) and by confocal microscopy (Zeiss 510; Carl Zeiss). Areas of vaso-obliteration and vitreoretinal neovascular tufts were quantified by using ImageJ software (developed by Wayne Rasband, National Institutes of Health, Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html) as reported.

**RT-PCR Assay**

Total RNA was isolated using a kit (RNA 4PCR kit; Applied Biosystems, Austin, TX) according to the manufacturer’s instructions. Total RNA was reverse transcribed with reverse transcriptase (M-MLV; Invitrogen).

---

**Table 1. Mouse Body Weights by Postnatal Day and Group**

<table>
<thead>
<tr>
<th></th>
<th>P17 (n = 17)</th>
<th>P20 (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OIR</td>
<td>5.1 ± 0.1</td>
<td>5.9 ± 0.1</td>
</tr>
<tr>
<td>HT (75% O2)</td>
<td>5.3 ± 0.2</td>
<td>5.8 ± 0.1</td>
</tr>
</tbody>
</table>

n, number of mice.
to generate cDNA. Quantitative PCR was performed (StepOne PCR system; Applied Biosystems) with Power SYBR Green.27 The fold difference in various transcripts was calculated by the CT method using 18S as the internal control. After PCR, a melting curve was constructed in the range of 60°C to 95°C to evaluate the specificity of the amplification products. Primer sequences for mouse transcripts are shown in Table 2.

ELISA

Mouse eyeballs (or retinas) were lysed by sonication with RIPA lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA) supplemented with protease inhibitors. The lysate was cleared of debris by centrifugation, and the supernatant was used for ELISA with a mouse VEGF ELISA kit (R&D Systems). Protein concentration in the lysates was determined by a BCA assay (Pierce Biotechnology, Rockford, IL). VEGF concentration was normalized to total protein in the lysate and then calculated as fold increase relative to the control.

Statistical Analysis

The results are expressed as mean ± SEM. Group differences were evaluated by using one-way ANOVA followed by post hoc Student’s t-test. Results were considered significant at \( P < 0.05 \).

RESULTS

HT Accelerates Retinal Revascularization in Pre-Proliferative Ischemic Retinopathy and Prevents NV

Studies were performed in the mouse model of ischemic retinopathy (OIR) in which obliteration of the immature retinal vessels is induced by exposure to 75% oxygen from P7 through P12. Immediately on return to room air, the avascular central retina becomes hypoxic, leading to upregulation of many angiogenic and inflammatory genes.28 However, vitreous NV is not initiated until P15, which is 3 days after the onset of retinal hypoxia.25–29 This model has been widely used for studies of mechanisms and strategies for the blockade of pathologic effects were highly significant by P20, at which time retinal NV showed a reduction of NV by 98%, though improved revascularization was not yet evident (Supplementary Fig. S1, http://www iovs arvojournals org/lookup/suppl doi:10.1167 iovs.11-7666/- DCsupplemental).

HT Increases the Formation of Endothelial Tip Cells

To examine potential cellular mechanisms underlying the beneficial effects of HT, the formation of endothelial tip cells was analyzed at P17 after 3 days of HT. Endothelial tip cells are critical for the development of new capillaries. They are characterized by the presence of specialized apical filopodia that mediate directional migration. Their migration is thought to be guided in part by receptor-mediated responses to cytokine gradients and by interactions with astrocytes, extracellular matrix, and cell surface adhesion molecules. In OIR, these cells were notably sparse at the junction of the vascular and avascular retina on P17 (Fig. 3). In areas lacking endothelial tip cells, the capillaries were poorly developed, and pathologic extension of vessels into the vitreous was present. On the other hand, in mice treated with hyperoxia beginning on P14, the density and distribution of endothelial tips cells was increased 3.4-fold compared with untreated controls (Fig. 3E), indicating that cellular and molecular factors critical to a normal angiogenic response were rescued.

HT Rescues Astrocytes

Astrocytes form the vascular template that guides physiological angiogenesis during retinal development.37,38 Aberrant astrocyte function, such as overactive CK2 or hypoxia-induced astrocyte degeneration, is involved in ischemia-induced vitreous neovascularization.22,39,40 OIR retinas analyzed on P17 showed extensive alterations in astrocyte morphology and distribution. The density of astrocytes in the central retina was increased, and many showed a spindle-shaped morphology with extensive overlapping (Fig. 4A). In mice treated with HT, astrocytes in the central retina formed a better network than those with OIR and retained their normal stellate/dendritic morphology (Fig. 4A). Their distribution was also more uniform and lacked the irregular overlap and variations in density seen with OIR. The transition zone between the vascular and avascular retina was also a transition zone for astrocyte morphology and distribution (Fig. 4B) in both OIR and hyperoxia-

<table>
<thead>
<tr>
<th>Gene Name</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEGF</td>
<td>TACCTCCACCACTGGCAAAGTG</td>
<td>TGATGGAACCTTCTCCTCCTT</td>
</tr>
<tr>
<td>FGF-2</td>
<td>TGTTAAGGAGGCTGGAAAGAGA</td>
<td>TCCAGGTCCTGGTTTGGAT</td>
</tr>
<tr>
<td>PDGF-A</td>
<td>GTTGGTGAGGCGGCGGAGAG</td>
<td>AGTGGGGTCTGGGCCATAGAA</td>
</tr>
<tr>
<td>Ang2</td>
<td>AGACCGAGAAGATGGGATGTTG</td>
<td>TATGCAGGTCCTGGCTCTAAGAA</td>
</tr>
<tr>
<td>EPO</td>
<td>GCTCCAGCCGCCTCATCTGGT</td>
<td>TTGGCAGGTCGAGGATGAGA</td>
</tr>
<tr>
<td>IGF-8</td>
<td>AGGTTGTTGCCACAGCACACA</td>
<td>TGGCGAGTCAGGAGGATGAGA</td>
</tr>
<tr>
<td>TNF-α</td>
<td>GGTTCCAAAAGGAGTTGAAA</td>
<td>TGGAGGTCGAGGCAATAGAA</td>
</tr>
<tr>
<td>MCP-1</td>
<td>GGCCTACGGCCATTGAGTGAACATTTA</td>
<td>CCTACTCACTCGGAGTACCTGCTCCTT</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>CGATGCGCTGCTGTCTCTGGA</td>
<td>GGGAAAAAGAAAACACACGTTGAT</td>
</tr>
<tr>
<td>uPAR</td>
<td>GGGCCGGTCTGGGAAAGCTTTG</td>
<td>TCTGGTCAGGAAGGTGAGAGG</td>
</tr>
<tr>
<td>PAI-1</td>
<td>GCAAGCCCTGCGACAGGTCTTCA</td>
<td>CGAAGAGGTCGAGGACTGCTT</td>
</tr>
<tr>
<td>GFAP</td>
<td>CGACTCGGACCGAGGAGG</td>
<td>GAGTGGACGACGACGTTG</td>
</tr>
</tbody>
</table>

Table 2. Primers Used for qPCR
treated eyes. In areas with a capillary plexus, astrocytes were evenly distributed and were arranged in a reticular configuration, mirroring the capillaries. In HT-treated eyes, the density of capillaries was reduced compared with OIR eyes, though the capillaries that were present conformed to the template of underlying astrocytes. The formation of an astrocyte plexus slightly preceded the leading edge of developing capillaries, similar to the pattern described for developmental angiogenesis in the neonatal mouse retina.37

**HT Reduces GFAP Expression in Müller Cells**

Müller cells are activated and involved in the development of pathologic angiogenesis.41,42 The reaction of Müller cells was determined by immunolabeling GFAP, a marker for Müller cell activation.43 Under normoxic conditions, GFAP-containing intermediate filaments are robustly expressed in processes associated with the superficial and deep vessels (Fig. 5A). OIR induces the activation of Müller cells in the central retina during the ischemic phase, as indicated by their robust expression of GFAP-containing filaments throughout their processes. Activation is minimal in peripheral areas of the retina, where capillary perfusion is preserved. Although GFAP expression in the nerve fiber layer is not changed, its expression in the Müller cell body in the central retina is suppressed by HT (Fig. 5A) compared with OIR. Quantitative PCR analysis of whole retina on P17 demonstrates that ischemia-induced expression of GFAP mRNA (11.6 ± 1.2-fold of control) is completely blocked by HT (1.2 ± 0.1-fold of control) (Fig. 5B). The expected lag between decreased mRNA expression and turnover of intermediate filament proteins would explain the residual GFAP immunolabeling seen on P17 in the HT retinas in spite of mRNA levels having already returned to normal.

**HT Normalizes Molecular Mediators of Angiogenesis and Inflammation**

To investigate the molecular mechanisms underlying the beneficial effect of HT, the expression of known mediators of NV,
including angiogenic factors (VEGF, FGF-2, PDGF-A, angiopoietin 2, erythropoietin, IGFBP-3), inflammatory molecules (TNF-α, ICAM-1, MCP-1, iNOS), and extracellular proteolytic molecules (urokinase plasminogen activator receptor [uPAR], PAI-1), were determined by quantitative PCR. As expected, the expression of these molecules is significantly increased by 0.4- to 54-fold after 2 or 5 days of OIR (Fig. 6). However, HT completely normalized the expression of each of these genes to the levels seen in the controls (non-OIR, room air). The observed downregulation of hypoxia-responsive genes, including VEGF and erythropoietin (EPO), suggests that HT decreases HIF-1α expression to normoxic levels. The downregulation of iNOS, ICAM-1, and MCP-1 suggests that supplemental oxygen also exerts a potent anti-inflammatory effect. Interestingly, PDGF-A, which is normally expressed by retinal ganglion cells and is known to play a prominent role in astrocyte recruitment and vascular patterning during retinal development, was not affected by either OIR or HT.

**Intravitreal Injection of a VEGF Antagonist Blocks Pathologic and Physiological Angiogenesis**

In addition to the increase in VEGF mRNA shown by quantitative PCR, analysis of VEGF protein in the retina also revealed close to a 3.2-fold increase that was decreased to the level of room air control by HT (1.2 ± 0.1-fold of control; Supplementary Fig. S2, http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7666/-/DCSupplemental). To compare the relative efficacy of HT with anti-VEGF therapy, VEGFR-1/Fc (VEGF trap) was administered by intravitreal injection on P14 in OIR mice. VEGF blockade potently suppressed vitreous NV by 79% but also blocked retinal revascularization and increased the avascular area by 82% (Fig. 7A).
induced further regression of the primary vascular plexus and thus reduced vascular density in the peripheral retina. These findings confirm the essential role of VEGF in normal retinal angiogenesis and in the formation of pathologic vessels in the vitreous. In contrast with the improved astrocyte morphology observed with HT (Fig. 4), alterations in astrocyte morphology and distribution found in VEGF antagonist-treated eyes were similar to those in vehicle-treated OIR eyes (Fig. 7B).

Intravitreal VEGF Does Not Cause Pathologic NV in Hyperoxia-Treated Eyes

HT effectively blocks the upregulation of VEGF in eyes made ischemic by OIR (Supplementary Fig. S2, http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7666/-/DCSupplemental). To test whether blockade of VEGF expression is the critical mechanism by which hyperoxia prevents vitreous NV, we administered exogenous VEGF intravitreally on P14 in mice receiving HT. Our results showed that HT continued to prevent NV in spite of a 5.3-fold elevated level of VEGF protein (Fig. 8), suggesting that VEGF is necessary but not sufficient for the development of extraretinal NV. Exogenous VEGF did not alter the rate of revascularization compared with hyperoxia alone.

DISCUSSION

Ischemic retinopathy is characterized by a period of retinal ischemia (pre-proliferative stage) caused by vessel regression or occlusion, followed by pathologic retinal NV (proliferative

**FIGURE 3.** HT increases tip cells in OIR. OIR mice were treated with hyperoxia (75% oxygen; HT) or were maintained in room air (OIR) from P14 to P17. Retinas were whole flat-mounted at P17. Representative images of retinal tip cells (white asterisk) and filopodia (yellow arrow) are shown. (A, B) OIR and HT. Original magnification, ×20. (C, D) High-magnification image from top of A and B. Original magnification, ×40. (E) Quantification of numbers of tip cells (n = 3 retinas from 3 mice). *P < 0.05 compared with OIR.
It is at the pre-proliferative stage of ischemic retinopathy that many patients first present to the ophthalmologist. Few therapeutic options exist at that point, and clinical observation for progression to NV is typically recommended. In this study, we determined the effects of supplying oxygen during the pre-proliferative stage of ischemic retinopathy. We demonstrate that HT with a range of oxygen concentrations after a period of retinal ischemia prevents the development of NV as effectively as supplying oxygen before the onset of retinal hypoxia in pre-proliferative ischemic retinopathy. Moreover, HT promoted the recovery and repair of damaged capillary beds within the retina, thus offering the possibility of significantly improving visual outcomes compared with current antiangiogenic or retinal ablative interventions. This study, together with previous studies showing similar beneficial effects when oxygen is supplied immediately after vessel regression but before retinal ischemia, indicates a broad therapeutic time window for HT in the pre-proliferative stage of ischemic retinopathy. The noninvasive and nondestructive nature of this intervention makes it particularly appealing for clinical use.

**Figure 4.** HT improves the status of astrocyte network and morphology. OIR mice were treated with hyperoxia (75% oxygen; HT) or were maintained in room air (OIR) from P14 to P17. Mice maintained in room air (RA) from P1 to P17 are control. Retinal flatmounts were stained with isolectin B4 (red) and anti-GFAP (green). Representative confocal images are shown (n = 9 retinas from 9 mice). (arrows) Examples of astrocytes with different morphology in OIR (spindle-shaped) and HT (stellate). The punctate staining for GFAP in the flatmounts represents cross-sections of Müller cells expressing GFAP. Original magnification, ×20. (A) Central retina. (B) Revascularization area.
Thus far, only limited investigation of oxygen therapy in human ischemic retinopathy has been reported. Its use in human retinopathy of prematurity is limited by the clinical challenges of tightly controlling blood oxygenation in neonates whose conditions are unstable and by the potential for inducing oxygen-related pulmonary complications in the premature infant.44–46 In spite of these limitations, a randomized trial of supplemental oxygen did demonstrate a notable trend toward producing better retinal outcomes in infants with pre-threshold ROP.44 Oxygen therapy has also been evaluated in a small case series of patients with chronic diabetic macular edema 18 and was found to cause significant and prolonged reduction in central macular thickness and improved visual function. We are not aware of any trials evaluating oxygen therapy in patients with diabetic retinopathy with significant ischemia (pre-proliferative or proliferative); however, case reports have been published19,20 in which hyperbaric oxygen therapy has been successfully used in central retinal vein occlusion with good visual outcomes.

Because hypoxia is thought to be a driving force behind angiogenesis, it is surprising that hyperoxia promotes retinal vascular recovery. This observation suggests that key physiological differences exist between the control of reparative angiogenesis and developmental angiogenesis in the retina. Although we did not directly measure tissue oxygen levels in the retina, the fact that VEGF and EPO mRNA expression were reduced to normoxic control levels by hyperoxia indicates that relief of cellular hypoxia was biologically significant. These data suggest that the expansion and survival of capillary networks during retinal revascularization is neither sensitive to high levels of inspired oxygen nor critically related to hypoxia-driven expression of VEGF or EPO, as has been shown for capillaries involved in developmental angiogenesis.55,47 Although it has been reported that oxygen-induced vaso-obliteration is significantly reduced in the retinas of transgenic mice that overexpress PDGF-α or IGFBP-3 and is enhanced in mice lacking IGFBP-3,48–50 our analysis showed that PDGF-α expression in hyperoxia-treated eyes was not significantly different from PDGF-α expression in ischemic controls and that IGFBP-3 levels were reduced by hyperoxia to those of room air control mice, suggesting protection from hyperoxia during vascular repair is mediated by other factors. Clinically, these data indicate that the use of therapeutic oxygen is not likely to adversely affect retinal revascularization in pre-proliferative ischemic retinopathy used outside the early developmental window seen in premature infants.

One cellular mechanism that may explain the improved vascular recovery in HT-treated eyes is the emergence of increased numbers of endothelial tip cells. It has been shown that these cells, which are critical to angiogenesis, depend on a physiological gradient of VEGF acting through the KDR/flk-1 receptor.51 Such gradients may be disrupted in severely ischemic tissue. The presence of appropriately directed endothelial tip cells in HT retinas indicates active, directional endothelial cell migration,51,52 implying physiological rather than pathologic regulation of angiogenesis. Conversely, the relative paucity of tip cells in non-HT-treated eyes suggests a disruption of normal signaling and cell-cell interactions involved in revascularization.

HT-induced rescue of astrocytes may also be crucial because the migration of endothelial tip cells is thought to be mediated in part by their interaction with cell adhesion molecules such as R-cadherin, expressed on the surfaces of astrocytes.58 Our immunohistochemical analysis of GFAP expression indicates that HT decreases the activation of Müller glia and improves the status of the astrocyte network in the avascular areas, facilitating the formation of a temp-

![Figure 5](http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933460/ on 07/02/2018)
plate over which proliferating intraretinal capillaries can form. Appropriate astrocyte-endothelial cell interactions would not only promote repair of the superficial vascular plexus but would also serve to limit pathologic extension of the vessels into the vitreous, thereby maintaining proper vascular compartmentalization.

To identify critical molecular mediators involved in HT, we performed RT-PCR analysis of several genes known to play key roles in pathologic NV. These included angiogenic cytokines, inflammatory mediators, and extracellular proteolytic molecules involved in cell migration. Interestingly, HT normalized the expression of each of these genes, demon-

FIGURE 6. HT normalizes the expression of angiogenic, inflammatory, and proteolytic molecules in OIR. OIR mice were treated with hyperoxia (75% oxygen; HT) or were maintained in room air (OIR) from P14 to P17. Mice maintained in room air (RA) from P1 to P17 are control. mRNA levels of specified molecules in retinas were quantified by q-PCR and normalized to RA control (n = 6–9 retinas from 6–9 mice). *P < 0.05 compared with RA. #P < 0.05 compared with OIR.
strating its pleiotropic effect in ischemic retinopathy. Although it is not possible to determine from this analysis which of these many factors might have been most critical, it is reasonable to assume that all might have had important and potentially interdependent contributions. Supporting this notion, whereas administration of a VEGF antagonist was sufficient to block pathologic NV in normoxic eyes subjected to OIR, exogenously administered intravitreal VEGF did not promote pathologic NV in eyes treated with hyperoxia. Selective suppression of pathologic NV in the presence of elevated VEGF expression has also been achieved consistently in the rodent model of OIR by the pharmacologic inhibition of retinal iNOS, TNF-α, or the angiotensin type 1 receptor or by the activation of peroxisome proliferator-activated receptor gamma. In this regard, the pleiotropic effect of HT makes it an appealing therapeutic approach for ischemic retinopathy, particularly because it does not adversely affect vascular repair, as seen with VEGF blockade. However, it is also expected that the beneficial role of HT will be transient unless such treatment is maintained until physiological vascular repair is complete. Further investigation is needed to establish the relevant

**FIGURE 7.** Blocking VEGF inhibits NV and revascularization in OIR but does not prevent the disruption of the astrocyte network. OIR mice were intravitreally injected with PBS (Veh) or VEGF blocker (VEGFR1/Fc, 2 μg/eye) at P14. Retinal vasculature (isolectin B4, red) and astrocyte network (GFAP, green) were analyzed at P17 in flatmount. (A) Representative images of retinal flatmount and quantification of NV and avascular areas (n = 4 retinas from 4 mice). *P < 0.05 compared with Veh. Original magnification, ×5. (B) Representative confocal images of astrocyte in the central retina are shown (n = 4 retinas from 4 mice). Original magnification, ×20.
dose-response relationship of HT and to better define the key molecular and cellular mechanisms involved in tip cell formation, glial rescue, and vascular repair during such treatment.

References

**Hyperoxia Therapy in Ischemic Retinopathy 6395**